Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10613313 | Journal of Controlled Release | 2005 | 12 Pages |
Abstract
The aim of the present study was to develop an efficient DTPA liposome formulation designed for plutonium decorporation. DTPA was encapsulated in conventional (CL) and polyethylene glycol-coated stealth® liposomes (SL) prepared by extrusion followed by the freeze-thawing method and sizing from around 100 to 800 nm. DTPA encapsulation percentages were approximately 30% in CL of any size but dropped from 48% to 7% as the diameter of SL was reduced. The pharmacokinetics of [14C]-DTPA encapsulated in large and small vesicles was evaluated in rats after a single intravenous administration. Both liposomal composition and size reduction had a significant impact on pharmacokinetic parameters, inducing a marked increased in exposure of the body to DTPA and its delayed excretion. DTPA distribution was moderate in liver but enhanced in spleen and bone and was dose-dependent, especially when SL of 100 nm were given. In conclusion, small and stealth® vesicles have interesting properties in delivering DTPA to contaminated tissues.
Related Topics
Physical Sciences and Engineering
Materials Science
Biomaterials
Authors
Guillaume Phan, Amaury Herbet, Sophie Cholet, Henri Benech, Jean-Robert Deverre, Elias Fattal,